Nitrogen Or Sulfur Patents (Class 424/78.27)
-
Patent number: 8703117Abstract: Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG).Type: GrantFiled: July 23, 2012Date of Patent: April 22, 2014Assignee: Lifebond Ltd.Inventors: Orahn Preiss Bloom, Ishay Attar, Natalie Iram, Chagai Komlos, Meir Haber
-
Patent number: 8680202Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: August 10, 2012Date of Patent: March 25, 2014Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Patent number: 8673285Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for modulating the immune response of a subject. Other aspects of the invention concern methods for modulating the immune response of a subject by the use of the conjugate, complexes comprising, the sphingoid-polyalkylamine conjugate in combination with a biologically active molecule capable of modulating an immune response of a subject, compositions comprising the conjugate as well as kits making use of said conjugate. A preferred conjugate according to the invention is N palmitoyl D-erythro sphingosyl 1 carbamoyl spermine.Type: GrantFiled: June 17, 2004Date of Patent: March 18, 2014Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Biolab Ltd.Inventors: Yechezkel Barenholz, Aviva Joseph, Eliezer Kedar
-
Patent number: 8673286Abstract: The invention describes DOPA functionalized, branched, polyalkylene oxide materials that are useful as adhesives.Type: GrantFiled: April 8, 2008Date of Patent: March 18, 2014Assignee: Northwestern UniversityInventors: Phillip B. Messersmith, Jeffrey L. Dalsin, Bruce P. Lee, Sean A. Burke
-
Publication number: 20140056840Abstract: The present invention relates to a polymer comprising hindered primary amine groups bonded to the backbone of the polymer by way of an amide, ester, or thioester linkage. The polymer is particularly useful as an adjuvant, especially for isothiazolone, and as a dispersant and stain blocker in coatings formulations.Type: ApplicationFiled: August 23, 2013Publication date: February 27, 2014Applicants: ROHM AND HAAS COMPANY, DOW GLOBAL TECHNOLOGIES LLCInventors: Sudhakar Balijepalli, Douglas Raymond Hawkins, Kathleen Rising Manna, Lidaris San Miguel Rivera
-
Publication number: 20140056841Abstract: Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value.Type: ApplicationFiled: November 5, 2013Publication date: February 27, 2014Inventor: David J. Vachon
-
Patent number: 8652456Abstract: The present invention relates to aqueous preparations comprising at least one water-soluble or water-dispersible copolymer with cationogenic groups which comprises at least one monomer with at least one protonatable nitrogen atom and at least one further monomer copolymerizable therewith in copolymerized form, and at least one cosmetically acceptable carrier, where the pH of the aqueous preparation has a value in the range from pH 4 to pH 6.Type: GrantFiled: June 15, 2005Date of Patent: February 18, 2014Assignee: BASF SEInventors: Marianna Pierobon, Son Nguyen-Kim, Peter Hossel
-
Patent number: 8647613Abstract: The present invention has an object of providing a drug carrier capable of controlling in vivo pharmacokinetics. The present invention is directed to a drug carrier comprising a molecular assembly having a drug incorporated therein, and the above object can be achieved by a part of the amphiphilic molecules included in the molecular assembly being released from the molecular assembly by an external environmental change. The present invention utilizes a phenomenon that the hydrophilic-hydrophobic balance of the amphiphilic molecules is shifted toward hydrophilicity by an external environmental change and thus the amphiphilic molecules are freed from the molecular assembly.Type: GrantFiled: March 10, 2006Date of Patent: February 11, 2014Assignees: JCR Pharmaceuticals Co., Ltd., Waseda UniversityInventors: Shinji Takeoka, Yosuke Okamura, Hideo Kanazawa, Shuji Hisamoto, Kohei Kubota, Yosuke Obata
-
Patent number: 8647670Abstract: This invention discloses a preparation method for biocompatible rapid-gelating hydrogel. Wherein, hydrogel is formed by rapid chemical-crosslinking using the mixing and chemical-crosslinking reaction under specified conditions between several active compound components. The preparation method comprises the following steps: (1) The solution containing biocompatible thiolated macromolecular derivatives (component A) and biocompatible thiol reactive crosslinking agents (component B) mutually mix to form reactive mixture with specified crosslinking conditions; (2) the reactive mixture forms the hydrogel. The invention also discloses a preparation method for novel rapid-gelating hydrogel spray and an application in medical field. This invention has the advantages of good biocompatibility, no by-products, good stability, convenient use, small amount of raw materials used, suitable for many medical application, etc.Type: GrantFiled: June 10, 2008Date of Patent: February 11, 2014Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.Inventor: Xiaozheng Shu
-
Publication number: 20140030210Abstract: The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-?.Type: ApplicationFiled: September 26, 2013Publication date: January 30, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Stephen James BROCCHINI, Antony Robert GODWIN, Yiqing TANG, Andrew Lennard LEWIS
-
Patent number: 8633277Abstract: Methods for preparing polymer-drug conjugates are provided. The disclosed methods involve polymeric reagents comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. Related methods, compositions, preparations, and so forth are also provided.Type: GrantFiled: March 8, 2011Date of Patent: January 21, 2014Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
-
Patent number: 8603453Abstract: A composition comprising: (i) an anti-microbial agent; and (ii) an acidic co-polymer of the Formula (1) wherein: [A] is of Formula (9), [B] is of Formula (10), and [C] is of Formula (12), wherein: [X] is of Formula (11), wherein [A], [B] and [C] may occur in any order; T is an optionally substituted substituent; L and G each independently is an optionally substituted linking group; R1, R2 and R3 are each independently H, optionally substituted C1-20-alkyl or optionally substituted C3-20-cycloalkyl; R4 and R5 are each independently H or C1-4-alkyl; q is 15 to 1000; p is 3 to 50; J is an optionally substituted hydrocarbyl, group; F is an acidic substituent; b is 0, 1, or 2; m is 0 to 350; n is 1 to 75; v is 1 to 100; and w is 1 to 4; provided that at least one of R4 and R5 is H and provided that R1, R2, R3, T, L, J and G do not contain a basic group; and wherein the pka value of the acidic substituent F on the monomer from which [C] is derived is less thanType: GrantFiled: May 20, 2004Date of Patent: December 10, 2013Assignee: Arch UK Biocides LimitedInventors: David John Hodge, David Alan Pears, John Jeffrey Gerrard, Paula Louise McGeechan
-
Publication number: 20130295040Abstract: The application provides a method of producing a comb polymer comprising the steps of: (a) Providing: (i) a plurality of monomers which are linear, branched or star-shaped, substituted or non-substituted, and have an olefinically unsaturated moiety, the olefinically unsaturated moiety being capable of undergoing addition polymerisation; (ii) an initiator compound; the initiator compound comprising a homolytically cleavable bond. (iii) a catalyst capable of catalysing the polymerisation of the monomer; and (b) Causing the catalyst to catalyse, in combination with the initiator, the polymerisation of a plurality of the monomers to produce the comb polymer. Catalysts and polymers obtainable by the process are also provided. Preferably, the comb polymer is capable of binding proteins and may be produced from monomers which are alkoxy polyethers, such as poly(alkyleneglycol) or polytetrahydrofuran.Type: ApplicationFiled: April 5, 2013Publication date: November 7, 2013Inventor: Warwick Effect Polymers Limited
-
Publication number: 20130287726Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.Type: ApplicationFiled: July 15, 2013Publication date: October 31, 2013Inventors: Gera NEUFELD, Boaz Kigel, Ofra Kessler, Asya Varshavsky
-
Patent number: 8545830Abstract: Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject.Type: GrantFiled: March 24, 2004Date of Patent: October 1, 2013Assignee: University of Tennessee Research FoundationInventors: Tao Lu Lowe, Young Shin Kim, Xiao Huang
-
Publication number: 20130243720Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.Type: ApplicationFiled: June 27, 2012Publication date: September 19, 2013Inventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
-
Publication number: 20130236528Abstract: The present invention provides an allergen inhibitor which effectively prevents allergens from reacting with specific antibodies, mitigates the allergic symptoms or prevents appearance thereof, and is less likely to cause unpredictable discoloration and discoloration under usual conditions. The allergen inhibitor of the present invention comprises an allergen-inhibiting compound including a linear polymer having at least one of substituents represented by the formulas (1) to (3) at a side chain. Thus, the allergen inhibitor of the present invention shows excellent allergen-inhibiting effects.Type: ApplicationFiled: April 25, 2013Publication date: September 12, 2013Applicant: Sekisui Chemical Co., Ltd.Inventors: Akihiko FUJIWARA, Taro SUZUKI, Mitsuhito TERAMOTO, Taro SUZUKI, Mitsuhito TERAMOTO
-
Publication number: 20130236416Abstract: The present invention generally relates to surface modified colloidal particles. The invention further relates to methods of preparing and methods of using the same.Type: ApplicationFiled: March 7, 2013Publication date: September 12, 2013Applicant: Clemson UniversityInventors: Parul Rungta, Michael Daniele, JR., Stephen H. Foulger, Ragini Jetty
-
Patent number: 8529935Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: GrantFiled: January 29, 2010Date of Patent: September 10, 2013Assignees: Mero S.R.L., Novagenit S.R.L.Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Patent number: 8524213Abstract: Disclosed are highly resilient and cohesive gels formed by the cross-linking of hyaluronan or hylan, their salts or derivatives thereof, using divinyl sulfone (DVS) as the cross-linking agent. Also disclosed are viscoelastic fluids containing alkylsulfone groups covalently attached to the backbone of the polymer, formed by the mono-functionalization of the cross-linking monomer DVS with hyaluronan and/or hylan. Mechanical properties such as values of hardness and cohesiveness are specified by the rheological properties of the gels. Also disclosed are methods for the preparation of such products. They have use in many applications as injectable and/or implantable devices and as drug delivery systems.Type: GrantFiled: June 26, 2006Date of Patent: September 3, 2013Assignee: Genzyme CorporationInventors: Adelya K. Leshchiner, Paul Konowicz, Min-Yeh Grace Chang, Valentina Vasilyeva
-
Publication number: 20130224256Abstract: The various embodiments herein provide hydrogel nanocomposite wound dressing comprising a polymeric basal matrix, a reinforcing agent, a biological sensor and an antibiotic for a slow release in a wound when applied. The polymeric basal matrix is made up of polyvinyl alcohol polymer with an amount of 1-15% by weight. The reinforcing agent comprises clay nanoparticles to inhibit a sudden drug release. The clay nanoparticles comprise montmorillonite nano particles with an amount of 0-2% by weight. The biological sensor is a peptide chain. The peptide chain is thrombin sensitive with an amount from 50 to 200 mg. The antibiotic is gentamycine with an amount of 1-3% by weight. The embodiments herein also provide a method of synthesizing the hydrogel nanocomposite wound dressing.Type: ApplicationFiled: February 25, 2012Publication date: August 29, 2013Inventors: Mohammad Mojmeli Renani, Mehran Solati Hashjin, Mohammad Rabiee, Yasaman Ganji, Leila Parsa, Masoomeh Mojmeli Renani
-
Patent number: 8518388Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: January 11, 2013Date of Patent: August 27, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Publication number: 20130216599Abstract: Antimicrobial parylene coatings and methods for their vapor-phase deposition.Type: ApplicationFiled: March 14, 2013Publication date: August 22, 2013Applicant: SPECIALTY COATING SYSTEMS, INC.Inventor: Specialty Coating Systems, Inc.
-
Publication number: 20130216494Abstract: One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.Type: ApplicationFiled: May 25, 2011Publication date: August 22, 2013Applicant: SynDecRx, Inc.Inventor: John S. Petersen
-
Publication number: 20130195791Abstract: Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): wherein R? is derived from a compound comprising at least one reactive amide group, R? is derived from a compound comprising at least one reactive aminooxy group, and X is H, CnH(n+2) or other atoms. Additional methods are also provided.Type: ApplicationFiled: December 21, 2012Publication date: August 1, 2013Inventors: Cory Berkland, Joshua Sestak
-
Publication number: 20130189219Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: March 19, 2013Publication date: July 25, 2013Applicant: AMGEN INC.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Patent number: 8492488Abstract: Disclosed are water soluble polymeric conjugates comprising the structure POLY-[Y—S—S-A]x, where POLY is a water soluble polymer; Y is a hydrocarbon-based spacer group, x is 1 to 25, S—S is a disulfide group attached to an sp3 hybridized carbon of Y; and A is a covalently linked residue of a pharmacologically active molecule. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are polymeric reagents useful to prepare such conjugates, and methods of their formation and use.Type: GrantFiled: June 20, 2012Date of Patent: July 23, 2013Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel P. McManus
-
Publication number: 20130177523Abstract: Described herein are gold particles that can be used to reduce tumor proliferation and treat cancer. In certain aspects, the gold particles can be modified in order to enhance selectivity and uptake of the particles by cancer cells. In certain aspects, the modified gold particles have a targeting group attached to the particle via a linker. The gold particles described herein can be used in combination with other anti-cancer agents in order to enhance overall cancer treatment. Methods for making and using the gold particles are also described herein.Type: ApplicationFiled: July 13, 2011Publication date: July 11, 2013Applicant: University of Utah Research FoundationInventors: Hamid Ghandehari, Adam Gormley, Abhijit Ray, Nate Larson
-
Publication number: 20130171092Abstract: The high temperatures required for cracking the cyanoacrylate oligomers, produced by the Knovenagel condensation of formaldehyde and a cyanoacetate, limit the synthetic diversity and the number of different side chains that can be incorporated into a cyanoacrylate prepared using this method. Accordingly, the diversity of cyanoacrylate monomers prepared industrially is quite limited. Disclosed herein is a method for the preparation of alpha-Cyanoacrylate ester monomers from a variety of phosphonium and ammonium alpha-cyanoacrylate salts.Type: ApplicationFiled: February 26, 2013Publication date: July 4, 2013Applicant: Henkel Ireland LimitedInventor: Henkel Ireland Limited
-
Patent number: 8475781Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: August 10, 2012Date of Patent: July 2, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark Davis, Kay T. Khin
-
Patent number: 8476404Abstract: This invention relates to polyhydric compounds containing primary and secondary hydroxyl groups selectively conjugated with linkers, polymers, and/or bioactive agents.Type: GrantFiled: July 3, 2009Date of Patent: July 2, 2013Inventor: Bhalchandra Shripad Lele
-
Publication number: 20130156722Abstract: Described herein are biodegradable drug delivery conjugates for effectively delivering bioactive agents to a subject. The drug delivery conjugates comprise a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first (main-chain) cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof. The conjugates possess numerous advantages over prior art delivery conjugates. Also described herein are methods for making and using the conjugates.Type: ApplicationFiled: March 7, 2011Publication date: June 20, 2013Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Pavla Kopecková, Huaizhong Pan, Jiyuan Yang, Jindrich Kopecek, Kui Luo
-
Publication number: 20130156723Abstract: This invention discloses ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a plurality of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit, suppress, block, or disrupt, simultaneously and independently, the functional domain of a different disease causing protein.Type: ApplicationFiled: January 2, 2013Publication date: June 20, 2013Inventor: LUCIA IRENE GONZALEZ
-
Publication number: 20130115165Abstract: Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivaties like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%; and acrylic acid (AA), at a molar ration of about 10% to about 30%.Type: ApplicationFiled: October 12, 2012Publication date: May 9, 2013Inventors: Anirban Maitra, Georg Feldmann, Savita Bisht
-
Patent number: 8436119Abstract: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same. That is, the present invention is an allergen suppressor, which contains a hydrophilic polymer and a component suppressing an allergen.Type: GrantFiled: January 10, 2013Date of Patent: May 7, 2013Assignee: Sekisui Chemical Co., Ltd.Inventors: Taro Suzuki, Mitsuhito Teramoto, Akihiko Fujiwara
-
Patent number: 8425893Abstract: Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.Type: GrantFiled: July 13, 2011Date of Patent: April 23, 2013Assignee: Warsaw Orthopedic, Inc.Inventors: David A. Knaack, John Winterbottom, David R. Kaes, Todd M. Boyce, Lawrence A. Shimp
-
Patent number: 8404793Abstract: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same. That is, the present invention is an allergen suppressor, which contains a hydrophilic polymer and a component suppressing an allergen.Type: GrantFiled: January 7, 2004Date of Patent: March 26, 2013Assignee: Sekisui Chemical Co., Ltd.Inventors: Taro Suzuki, Mitsuhito Teramoto, Akihiko Fujiwara
-
Patent number: 8404784Abstract: A novel process of manufacturing sevelamer carbonate from a polyallylamine carbonate or bicarbonate chloride salt. Process for manufacture of carbonate and/or bicarbonate salts of water insoluble polymers containing amino groups that are useful as anion binders in the gastrointestinal (GI) system. The process arranges the polyallylamine chain in a solution in such a way that the cross-linking reaction with epichlorohydrin can be controlled at a desired reaction rate.Type: GrantFiled: December 2, 2009Date of Patent: March 26, 2013Assignee: Navinta LLCInventors: Christopher N. Jobdevairakkam, Hero Velladurai
-
Publication number: 20130071449Abstract: An implantable device including a conjugate formed of an acrylamide-based copolymer and a bioactive agent is provided.Type: ApplicationFiled: November 14, 2012Publication date: March 21, 2013Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.Inventor: Abbott Cardiovascular Systems Inc.
-
Patent number: 8394366Abstract: A process for preparing a thermosensitive polymer from a microemulsion is provided. The microemulsion comprises a monomer capable of forming a thermosensitive polymer and a polymerizable surfactant. Additional comonomers may be included in the microemulsion to vary the properties of the polymers produced. The resulting thermosensitive polymers may be nanoporous. The polymers according to the invention are suitable for use in medical applications, including use as a wound dressing and for delivery of cells to a graft site.Type: GrantFiled: April 15, 2004Date of Patent: March 12, 2013Assignee: Agency for Science, Technology and ResearchInventors: Yi Yan Yang, Li Shan Wang
-
Patent number: 8389661Abstract: The invention relates to an amphiphilic-BMP polymer complex which is physically and chemically stable and soluble in water, characterized in that: the amphiphilic polymers comprise a hydrophilic polysaccharide skeleton functionalized with hydrophobic substituents and hydrophilic groups the BMP is selected from the group of therapeutically active BMPs (Bone morphogenetic Proteins), the polymer/BMP mass ratio is lower than or equal to 700. The invention also relates to the process for preparing the amphiphilic-BMP polymer complex in an aqueous medium and in the absence of organic solvents likely to denature the protein. The invention also relates to therapeutic compositions of an amphiphilic-BMP polymer complex according to the invention.Type: GrantFiled: July 25, 2008Date of Patent: March 5, 2013Assignee: ADOCIAInventors: Gerard Soula, Olivier Soula, Remi Soula
-
Publication number: 20130052155Abstract: The present invention encompasses methods and compositions for generating a biomimetic proteoglycan. The invention includes methods of treating a disease, disorder, or condition of soft tissue using a biomimetic proteoglycan.Type: ApplicationFiled: November 9, 2010Publication date: February 28, 2013Inventors: Michele Marcolongo, Edward Vresilovic, Benjamin Jackson, Sumona Sarkar, Caroline Schauer
-
Patent number: 8383092Abstract: The invention describes substrates, such as prosthetics, films, nonwovens, meshes, etc. that are treated with a bioadhesive. The bioadhesive includes polymeric substances that have phenyl moieties with at least two hydroxyl groups. The bioadhesive constructs can be used to treat and repair, for example, hernias and damaged tendons.Type: GrantFiled: September 28, 2009Date of Patent: February 26, 2013Assignee: KNC NER Acquisition Sub, Inc.Inventors: Bruce P. Lee, Laura Vollenweider, John L. Murphy, Fangmin Xu, Jeffrey L. Dalsin, Jeanne Virosco, William Lew, Jed White
-
Publication number: 20130040026Abstract: A method of producing a liquid substantially free of beverage spoiling microorganisms, characterized in that said method comprises steps of: (a) obtaining a liquid; (b) obtaining a bioactive material that does not affect a predetermined set of organoleptic parameters of said liquid upon contact with said concentrate for a predetermined length of time; and, (c) treating said liquid with said bioactive material until the concentration of beverage-spoiling microorganism falls below a predetermined threshold.Type: ApplicationFiled: December 2, 2010Publication date: February 14, 2013Inventors: Shmuel Bukshpan, Gleb Zilberstein
-
Patent number: 8357361Abstract: Bioabsorbable macromer compositions are provided including a diisocyanate-functional bioabsorbable polymer. In some embodiments, the diisocyanate-functional bioabsorbable polymer can be combined with a functionalized polyol. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.Type: GrantFiled: November 17, 2010Date of Patent: January 22, 2013Assignee: Covidien LPInventors: Ahmad R. Hadba, Nadya Belcheva
-
Publication number: 20130011363Abstract: Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: UNIVERSITY OF WASHINGTONInventors: Shaoyi Jiang, Shengfu Chen, Zheng Zhang, Gang Cheng, Hong Xue, Louisa R. Carr
-
Publication number: 20130011456Abstract: Antimicrobial parylene coatings and methods for their vapor-phase deposition.Type: ApplicationFiled: July 6, 2012Publication date: January 10, 2013Inventors: Rakesh Kumar, Yingfei Ke, Dustin England
-
Publication number: 20120328556Abstract: A comb-like surfactant polymer for changing the surface properties of biomaterials is described. The surfactant polymer comprises a polymeric backbone of repeating monomeric units having functional groups for chemically attaching to side chains, a plurality of hydrophobic side chains attached to the backbone via the functional groups and a plurality of hydrophilic side chains chemically attached via functional groups to the polymeric backbone. The hydrophilic side chains providing anti-thrombogenic properties to the surfactant. An antimicrobial agent selectively attached to some hydrophilic side chains thereby providing additional antimicrobial properties to the surfactant. The surfactant polymer may be applied to the surface of medical devices to reduce the surfaces thrombogenicity and decrease the number of microorganisms on the surface.Type: ApplicationFiled: June 27, 2012Publication date: December 27, 2012Applicant: Greatbatch Ltd.Inventors: Jan J. Lewandowski, Yubiao Liu
-
Patent number: 8337881Abstract: A polymerizable antimicrobial formulation for forming a wound closure adhesive comprising cyanoacrylate monomer and diiodomethyl-p-tolylsulfone; and a method for closing the approximated edges of a wound with a polymeric film that substantially inhibits the growth of microorganisms, where the polymeric film is formed by use of the polymerizable antimicrobial formulation.Type: GrantFiled: August 16, 2004Date of Patent: December 25, 2012Assignee: Ethicon, Inc.Inventors: Binoy K. Bordoloi, Shubhangi R. Bhende
-
Patent number: 8323632Abstract: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the overall structure of the copolymer comprises an inner core region that includes the central core and the inner polypeptide segment, while the outer core region is hydrophilic in nature. The multi-arm copolymer of the invention is particularly useful for delivery of biologically active agents that can be entrapped within the inner core region.Type: GrantFiled: June 2, 2011Date of Patent: December 4, 2012Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Zhongxu Ren, Kazunori Emoto